Nuvalent, Inc.
NUVL
Rank in Stocks
#2105
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Share Price
$123.96
Last synced: 2026-07-21
Market Cap
$9.75B
Change (1 day)
0.00%
Change (1 year)
26.53%
Country
US
Trade Nuvalent, Inc. (NUVL)
Category
Healthcare
Earnings for Nuvalent, Inc. (NUVL)
Earnings in Mar 2026 TTM: $-449.48M
According to Nuvalent, Inc. latest financial reports the company's current earnings are $-449.48M. In 2023 the company made an earning of $-126.22M, a decrease compared to its 2022 earnings that were of $-81.85M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Nuvalent, Inc. from 2019 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-449.48M | 72.88% |
| 2024 | $-259.99M | 105.98% |
| 2023 | $-126.22M | 54.20% |
| 2022 | $-81.85M | 76.65% |
| 2021 | $-46.34M | 218.34% |
| 2020 | $-14.56M | 23.26% |
| 2019 | $-11.81M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -1,273.56% |
US
|
|
| $-3.09B | 586.80% |
US
|
|
| $-4.02B | 793.52% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -533.98% |
NL
|
